PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Adagrasib→

Adagrasib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2326521-71-3
Molecular formula
C32H35ClFN7O2
Molecular weight
604.1 g/mol
Drug class
Targeted antineoplasticirreversible KRAS G12C inhibitor
Mechanism of action
Irreversibly and covalently binds the mutant cysteine in KRAS G12C, locking the mutant protein in its inactive state and preventing downstream signalling without inhibiting wild-type KRAS.
Indications / reported uses
  • As monotherapy for adults with KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer after at least one prior systemic therapy (accelerated approval; continued approval may depend on confirmatory evidence)
  • In combination with cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy

Sources: NLM DailyMed — KRAZATI (adagrasib), updated 31 Aug 2026 · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Adagrasib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Adagrasib Permitted Daily Exposure (PDE) report (the Adagrasib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Adagrasib Occupational Exposure Limit (OEL) report (the Adagrasib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.